Intracellular signaling cascades are a series of regulated protein-protein interactions that may provide a number of targets for potential drug discovery. Here, the authors examine the interaction of regulators of G-protein signaling (RGS) proteins with the G-protein Gαo, using a flow cytometry protein interaction assay (FCPIA). FCPIA accurately measures nanomolar binding constants of this protein-protein interaction and has been used in high-throughput screening. This report focuses on 5 RGS proteins (4, 6, 7, 8, and 16). To increase the content of screens, the authors assessed high-throughput screening of these RGS proteins in multiplex, by establishing binding constants of each RGS with Gαo in isolation, and then in a multiplex format with 5 RGS proteins present. To use this methodology as a higher-content multiplex protein-protein interaction screen, they established Z-factor values for RGS proteins in multiplex of 0.73 to 0.92, indicating this method is suitable for screening using FCPIA. To increase throughput, they also compressed a set of 8000 compounds by combining 4 compounds in a single assay well. Subsequent deconvolution of the compounds mixtures verified the identification of active compounds at specific RGS targets in their mixtures using the polyplexed FCPIA method. (Journal of Biomolecular Screening 2009: 610-619) 
INTRODUCTION
I nhibition of protein-protein interactions represents a unique approach to disrupting intracellular signaling networks. Technically, directly measuring protein-protein interactions has been difficult, often relying on fluorescence polarization (FP) assays, which use a representative peptide and 1 complete protein moiety to assess the interaction. Other often used methods are surface plasmon resonance (SPR), time-resolved fluorescence resonance energy transfer (TR-FRET), and AlphaScreen  (Perkin Elmer, Waltham, MA), which also have significant limitations with regard to protein size and purity, as well as a number of intrinsic experimental factors, such as buffer composition, that can affect the signal quality. The strength of signal may also be of issue in both FP and SPR methods, which does not necessarily render them uninformative, but significant optimization of protocols is often necessary. Furthermore, some limitations for these methods exist when considering the goal of discovering new small molecule inhibitors of specific protein-protein interactions, in that they can require significant amounts of protein and peptide material in the case of FP, or may be far too slow for serious consideration for high-throughput screening, in the case of SPR. In addition, TR-FRET and AlphaScreen  require reagents, such as terbium or europium chelates that add significantly to assay cost. Successful cell-based assays have been developed for screening for inhibitors protein-protein interactions, using luciferase as a reporter, but an isolated protein-protein interaction can be difficult to distinguish in these systems, and offtarget effects may be present. 1, 2 Because of the aforementioned limitations of existing methodologies, our group and others have had long-standing interest in the implementation of flow cytometry for investigating protein-protein and protein-ligand interactions. [3] [4] [5] [6] [7] [8] [9] Recent publication of a flow cytometry proteinprotein interaction assay (FCPIA) developed as a high-throughput screening method for screening for inhibitors of regulator of G-protein signaling 4 (RGS4) is exemplar of the feasibility of using FCPIA to mine for RGS/Gαo interaction inhibitors. 3 Regulators of G-protein signaling (RGS) proteins are intracellular modulators of G-protein-coupled receptor signaling 10 and represent intriguing drug targets. 11, 12 Although cell-surface expressed ligand-binding domains, such as receptors and ion channels are commonly exploited targets, the inhibition of signal at the initiation of cascades usually results in complete shutdown of the signal. In contrast, inhibition of downstream protein-protein interactions allows manipulation of discrete steps of a signaling cascade that may result in more subtle and specific effects. [13] [14] [15] We are interested in chemically targeting the key regulatory interaction between RGS proteins and Gα subunits. Classically, the signals mediated by G-protein-coupled receptors (GPCRs) upon ligand binding are mediated through heterotrimeric G-proteins. Upon ligand binding and receptor activation, G-protein α and βγ subunits dissociate from receptor and modulate the activity of a number of downstream effectors, ranging from ion channels to adenylate cyclase. 16 The activation of the G-protein is dependent on the α subunit, which exists in a GDP liganded form in its inactive state and undergoes rapid GTP for GDP exchange upon activation. Inactivation of these G-protein-signaling pathways occurs when the bound GTP is hydrolyzed back to GDP and the Gα subunit returns to its inactive, GDP-liganded form. Gα subunits possess intrinsic GTPase activity, but this process is too slow to account for physiological processes such as cardiac and visual signal transduction. 17, 18 Physiological rates of G-protein inactivation are achieved through the action of RGS proteins. 19, 20 RGS proteins act as GTPase accelerating proteins (GAPs), which shorten the lifetime of the active Gα and Gβγ proteins from minutes to milliseconds or seconds. 21 A large percentage of therapeutic drugs target GPCRs, but we are interested in examining the RGS/Gα interaction as a unique target, because inhibiting an RGS could have several interesting physiological effects and perhaps better selectivity (for review, see Zhong and Neubig, 12 Traynor and Neubig, 22 and Neubig and Siderovski 23 ). For instance, an RGS inhibitor could potentiate the action of natural or exogenous agonist ligands. Specificity could also be introduced, relying on the discrete tissue expression patterns of some RGS proteins. For these reasons, our laboratory and others have been interested in modulating the RGS/Gα interaction, with successes ranging from our cyclic octapeptide and small molecule RGS inhibitors, to a small molecule that stabilizes an RGS/G-protein interaction, as well as inhibitors identified through a yeast 2-hybrid screen. 3, [24] [25] [26] [27] Our current goal is to expand on the highthroughput capabilities of the FCPIA method, by increasing the content of experiments and future screens to examine multiple RGS/G protein interactions simultaneously.
FCPIA consists of 3 key components ( Fig. 1) , 1) avidincoated microspheres, 2) biotinylated RGS, and 3) activated Gαo labeled with AlexaFluor  532. Experimentally, biotinylated RGS coupled to avidin-coated beads is co-incubated in a 96-well plate with activated Gαo. As samples from each well are aspirated into the Luminex flow cytometer, the bead is detected and bead-associated fluorescence is measured, providing a quantitative reading of the amount of Gαo bound to RGS. 3 In this study, we advance our ability to make quantitative proteinprotein interaction measurements in a multiplexed format. Lumavidin beads are available with 100 different internal dye ratios (regions), which the Luminex flow cytometer can distinguish in the flow cell. Therefore, multiple RGS proteins can be coupled to individual bead regions ( Fig. 1) , and then mixed together to perform binding analyses to a common, fluorescently labeled binding partner, in this case Gαo. In this study, we compare affinity measurements of 5 different RGS proteins to Gαo in individual (singleplex) to multiplex measurements. In addition, we established Z-factor values for a 5-plex RGS system to use in a high-throughput FCPIA paradigm, demonstrating the suitability of multiplexing protein-protein interaction measurements to measure individual protein-protein interaction affinities as well as for use in higher content FCPIA.
In this study, we introduce a new paradigm to screening small molecule libraries using flow cytometry. Because of the limitations of technology, in terms of throughput speed, we report the utilization of what we term a "polyplexed screen." In this paradigm, we have used 5 different RGS proteins on 5 different Luminex bead regions, allowing us to multiplex our 5 RGS targets in a single well. We chose these 5 RGS proteins because they belong to 2 separate RGS protein families (R4 and R7) to allow for the identification of RGS-family inhibitors, as well as being heterologously expressed in good quantity from Escherichia coli. For the RGS7 family members RGS7 and RGS6, we expressed the RGS homology domain (RH), because it is the minimal unit necessary to interact with Gαo and is stably expressed in E. coli. To increase the number of compounds that could be screened, we also performed a 4:1 compression of an 8000-compound subset of the Maybridge HitFinder library held by the University of Michigan Center for Chemical Genomics (CCG). For this compression, 4 compounds were deposited into each test well of a 96-well plate (80 wells, 16 used for controls), resulting in 320 compound entities per screening plate. Upon screening, 5 targets on beads were added to each well, increasing our data density to 20 data points per well (5 targets by 4 compounds), or 1600 data points per 96-well plate, a marked increase in the content of our screen from the normal 80 data points.
Due to the design of this prototype screen, it was necessary to perform a deconvolution of any hit wells to test our ability to detect and identify 1 active compound within a 4-compound mixture. After our initial screen and dose-response follow-up, we were able to identify active individual compounds from the 4-compound mixtures, the majority of which exhibited 1 active compound per well, with only 2 exceptions.
In this study, we explore the feasibility of performing 5-target multiplexing using FCPIA as well as using 4-compound mixtures as our screening library. We demonstrate the ability of this method to increase content with little time penalty and the robustness of the method in identifying a single active compound from our screening mixtures.
METHODS

Protein expression, purification, and labeling
RGS16. Human RGS16 in pcDNA3.1(+) vector was purchased from the UMR cDNA resource (www.cdna.org). The open reading frame containing full-length RGS16 was amplified using the following primers: 5′-GAATTCATGTGCCGCA CCCTGGCCGC-3′ and 5′-GTCGACGGTGTGTGAGGGCTC GTCCA-3′, which amplify the entire open reading frame and add compatible EcoNI and SalI restriction enzyme recognition sites on the 5′ and 3′ ends, respectively. The fragment was amplified using standard PCR conditions, gel-purified per manufacturer's protocol (Qiagen, Valencia, CA), and ligated into Antarctic phosphatase treated pMALC2H10T vector digested with EcoNI and SalI. The ligated product was transformed into DH5α bacteria, colonies picked, miniprepped (Qiagen), and sequenced to verify in-frame placement of RGS16 to form the maltose binding protein (MBP)-RGS fusion protein.
RGS6. The human RGS6 RGS homology domain (RH, box) was cloned from total human brain mRNA (Clontech, Mountain View, CA) using reverse transcriptase polymerase chain reaction (RT-PCR). The primers used for RT-PCR were designed to add restriction sites BamHI and SalI for cloning into pMALC2H10T were as follows: 5′-ATCCGAAAATGTCG ACGTT TGAAGA-3′ and 5′-AAGAAGAGAGGGCTGTAAACAGGAG-3′.
RT-PCR was performed using SuperScript  One-Step RT-PCR with Platinum  Taq from Invitrogen (Carlsbad, CA) as per the manufacturer's protocol using a 55 °C annealing temperature. The RT-PCR resulted in a ~600-bp product, detected by agarose gel electrophoresis and purified using a gel-purification kit (Qiagen). The PCR product was ligated into Antarctic phosphatase-treated pMALC2H10T expression vector cut with BamHI and SalI. The sequence was verified to be identical with the RGS6 box by sequence alignment with sequence available in the NCBI database.
RGS7 and RGS8. RGS7 RH domain, and full-length RGS8, were purified as GST-fusion proteins as previously described. 4 RGS4. An N-terminally truncated (∆N51) RGS4 pMAL-C2H10T DNA construct was a kind gift from Dr. John Tesmer (University of Michigan). This construct expresses the RGS4 as a C-terminal fusion on the bacterial MBP. The construct expresses at much higher levels than other HIS-tagged or native RGS4 constructs; however, it binds Gαo with slightly lower affinity than a previously published ∆N18-RGS4 construct. 3
Generation of cysless RGS4 mutant
The following oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA) and used in the Quick-Change Multi Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Stratagene, La Jolla, CA). Mutagenesis was required to be completed in 2 rounds, due to C197 and C204 being localized too close to each other and causing primer overlap. The primer sequences are as follows:
Gαo. Rat Gαo was purified as an N-terminal 6X-HIS tagged construct expressed in E. coli as previously described. 28 Gαo activity was assessed using GTPγ 35 S binding. 29
General MBP-RGS fusion protein purification
For bacterial expression of MBP fusion proteins, vector was transformed into BL21(DE3) bacteria and a single colony was placed in 100 mL of enriched media with glucose (EMG) overnight, shaking at 37 °C. The next morning, 6 L of EMG was inoculated with the starter culture and grown to OD 600 = 0.6; 100 µM isopropyl β-d-1-thiogalactopyranoside (IPTG) was added and induction proceeded for 4 h at 37 °C. Bacteria were then pelleted, flash-frozen in liquid nitrogen. and stored at -80 °C until purification. In brief, frozen pellets were thawed in 50 mM HEPES, 100 mM NaCl, and 1 mM DTT, pH 7.2 (MBP buffer) with added protease inhibitors (E-64, phenylmethanesulfonylfluoride [PMSF], lima bean trypsin inhibitor, TPCK) and treated with 0.8 mg/mL lysozyme for 20 min. Following lysis, 1 mM (final) MgCl 2 and 8 µg/mL DNAse I were added while stirring. After 10 min, the lysate was centrifuged for 40 min at 35,000 RPM (~110,000 × g) in a Ti40 (Beckman, Fullerton, CA) rotor. The supernatant was filtered (0.45 µm) and applied to a 10-mL amylose column (New England Biolabs, Ipswich, MA). The column was washed with 200 mL of MBP buffer, and 1-mL fractions were eluted with 10 mM maltose in MBP buffer. Approximately 80% pure intact fusion protein eluted in fractions 3 to 12. Fractions were pooled, concentrated using an Amicon Ultra concentrator (Millipore, Billerica, MA), and snap-frozen in liquid nitrogen.
Chemical biotinylation of purified RGS proteins. RGS proteins were biotinylated with amine-reactive N-(+)-biotinyl-6aminocaproic acid N-succinimidyl ester (Biotin-NHS, Fluka 14412) in a 3:1 (biotin:RGS) stoichiometry as previously described. 3
Flow cytometry protein interaction assay
RGS single and multiplex saturation assay. Experiments were performed in 96-well conical-bottom PCR plates and samples were read using a Luminex  200  bead analyzer. The protocol used for single-RGS saturation experiments has been previously described. 3 In brief, Luminex LumAvidin beads (500 per RGS subtype per well) were vortex mixed, sonicated briefly, and diluted into 1 mL of bead coupling buffer (BCB) (PBS, pH 8.0, supplemented with 1% BSA). The beads were pelleted (60 sec at 7 K RPM) supernatant removed, and resuspended in 1 mL of BCB. This process was repeated for 3 washes. The beads were then resuspended in 500 µL of BCB and biotinylated RGS protein added at 20× the final desired concentration (10 nM, final). The beads were incubated for 30 min at room temperature (RT). After the bead coupling was complete, the beads were spun down, then washed with 1 mL of BCB 3 times. For multiplex assays, at this point the RGSbeads were combined and resuspended in 5 mL of flow buffer (50 mM HEPES, 100 mM NaCl, 0.1% Lubrol, 1% BSA pH 8.0). A total of 50 µL of beads was dispensed into each well of the 96-well plate and incubated at RT for 10 min. Blank beads (i.e., bead coupling reaction conditions in the absence of RGS) were used as controls in some experiments to determine nonspecific binding. During the 10-min incubation of RGS with compound, the AF532-labeled Gαo solution was prepared. GDP (5 µL, 10 mM), MgCl 2 (500 µL, 50 mM), AlCl 3 (500 µL, 50 µM), and NaF (500 µL, 50 mM) were added to 3.5 mL of flow buffer, and AF532-Gαo was added to form the activated Gαo-GDP-AlF 4 complex (at 200 nM final concentration), which binds RGS with high affinity. This solution was then diluted serially down the 96-well plate to yield final Gαo concentrations between 0.78 and 100 nM. (Note: For some experiments, the GDP control is Gαo added without the addition of MgCl 2 , AlCl 3 , and NaF to yield GDP-bound, and hence very low affinity [background] levels of RGS/Gαo binding.) After 10 min to ensure activation of the Gαo, 50 µL was aliquoted to each RGS-bead and compound-containing well of the 96-well screening plate. The proteins were incubated for 30 min at RT in the dark before being read on a Luminex  200  IS 96-well plate reading flow cytometer. Median fluorescence intensity values for each bead set (RGS) were calculated and used for data analysis.
Z-factor determination. Z factor was determined using the following equation
represents the standard deviation of positive and negative (p, n) controls, and µ represents the mean of positive and negative control values. Positive controls were determined using 48 wells of a 96-well plate, containing 5 RGS proteins on different bead regions at a final concentration of 10 nM, and the addition of AMF-treated Gαo (50 nM, final). Negative controls are treated in the same fashion, but substituting mock-coupled ("blank") beads for the RGS-coupled beads. DNA sequencing. All DNA constructs were verified by sequencing through the University of Michigan DNA Sequencing Core Facility.
Polyplexed high-throughput screen
A total of 8000 compounds from the Maybridge HitFinder collection were screened. In brief, 0.5 µL from each of 4 compound master plates (1.5 mM compound concentration in DMSO) was transferred via a Beckman BioMek XL liquid handling robot into the corresponding well of a 96-well assay plate. This resulted in a total of 2 µL of compound in each well of a 96-well plate. These concentrations kept DMSO concentrations below 4%, a conservative upper limit tolerance for the assay (data not shown). Well registry was preserved, with well A2 from master plates 1 to 4 being dispensed into well A2 of the assay plate, resulting in 96-well assay plates with 4 compounds per assay well. The assay format reserved rows 1 and 12 for positive and negative controls, leaving 80 experimental wells per plate that contained the compound mixtures.
Lumavidin microspheres were prepared as described above, and coupled to each of the 5 different RGS proteins. RGSbeads were added to compound-containing plates as a single 50-µL aliquot per well. A 10-min incubation at RT was followed by addition of 100 nM AlexaFluor  532-labeled Gαo in 50 µL of aliquot to yield a 50 nM final Gαo concentration. The mixture was incubated in the dark for 30 min at RT, and then read on a Luminex  200  bead analyzer, collecting 75 events per bead region per well. The final screening conditions per 100-µL volume in each well were: 50 nM AF532-labeled Gαo, 7.5 µM each screening library compound, 2% DMSO, and 10 nM each RGS on 500 beads. Positive controls (loss of Gαo binding signal) consisted of wells without MgCl 2 , AlCl 3 , and NaF (-AMF), and negative control wells (preserved Gαo binding signal) consisted of the screening mixture without any screening library compound.
Materials
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO), Fisher Scientific (Hampton, NH), or Acros Organics (Geel, Belgium) and were reagent grade or better. Avidin-coated microspheres for flow cytometry were from Luminex (Austin, TX). Molecular biology kits were purchased from sources indicated in the text. Data were analyzed using Graphpad Prism 5.0 (Graphpad Software, San Diego, CA).
Fluorescent labeling of Gαo. Purified Gαo was chemically labeled with AlexaFluor  532 carboxylic acid succinimidyl ester (Invitrogen, Carlsbad CA) at a 3:1 fluorophore: protein ratio. Purified Gαo (500 µg, 12.5 nmol) was diluted in 250 µL of H 50 E 1 N 100 (50 mM HEPES, 1 mM EDTA, 100 mM NaCl, pH 8) buffer supplemented with 10 µM GDP; 2.8 µL (~38 nmol) of an AF532 solution (1 mg/100 µL of DMSO) was added, and the solution was incubated at 4 °C in the dark for 1.5 h. The reaction was quenched with 20 µL of 1 M glycine and for 30 min. Excess fluorophore was removed via 1 mL of Sephadex G25 spin column and elution with HEN buffer supplemented with GDP. Activity and effective concentration of Gαo was determined postlabeling using GTPγ35S binding. 29 Flow cytometry dose-response experiments. Experiments were done similarly to the flow cytometry screening assay, except that the total assay volume was 150 µL, with 50 µL of RGS4-beads (coupled at 3× final concentration, 6 nM), 50 µL Gαo-AF532, and varying concentrations of CCG compounds to give a final range of 100 to 0.01 µM. Final assay concentrations for RGS and Gαo were 2 nM and 15 nM, respectively.
RESULTS
Effect of multiplexing RGS targets
We tested binding affinities between the RGS/Gα pairs to establish the multiplexed screening method. We compared the affinity measurements for 5 RGSs with their binding partner, Gαo, in both singleplex (1 RGS per sample) and multiplex (5 RGS per sample) assays. Nonspecific binding was determined using microspheres without bound RGS and was subtracted from total binding data to yield specific binding values. Nonspecific binding was less than 10% of total, except in the case of RGS6, in which nonspecific binding was approximately 15%. Figure 2 depicts the saturation isotherms for individual measurements of specific binding of the RGS proteins, whereas Figure 3 shows the same measurements made in multiplex. Table 1 summarizes the binding data. Notably, RGS 4, 7, 8, and 16 have K d values < 100 nM for Gαo, whereas RGS6 has a 3-to 4-fold lower affinity. Individual K d values for an individual RGS protein were not significantly different when measured in single and multiplex formats (p > 0.05).
Z-Factor determination
To assess the suitability of using multiplexed targets in the FCPIA screen, we determined Z factors for each RGS-Gαo pair in a multiplexed format. This used a 96-well plate with 5 distinct RGS-labeled beads plus soluble AlexaFluor  532labeled Gαo. Forty-eight wells were used for the positive controls in the presence of AlF 4 to stimulate high-affinity RGS-Gαo binding and 48 wells for negative controls in the absence of AlF 4 - (Fig. 4) . Z factors were as follows: 0.76 (RGS4), 0.73 (RGS6), 0.87 (RGS7), 0.92 (RGS8), 0.78 (RGS16). The Z factors were all well above the value of 0.5 that indicates an assay that is acceptable for high-throughput screening. 30 Table 2 summarizes the screening results from an 8000compound subset of the Maybridge HitFinder collection. The cutoff for defining an active was set at 60% inhibition of the RGS-Gαo interaction as measured using FCPIA. Table 2 depicts the number of active wells for each RGS, as well as the number of unique wells, indicating that a well showed activity for only a single RGS at the 60% cutoff. Subsequent cherry-picking and dose-response experiments were done on each of the 4 compounds from each unique active well, with 
Multiplex screening results
Compounds with multiple activities
During dose-response follow-up experiments with freshly ordered powders, compounds that were active on RGS4 family Table 3 summarizes the percentage of inhibition by the compounds on other RGS4 family members at 10 µM.
Potential mechanism of RGS inhibitors
To assess the potential role of cysteine modification in the mechanism of action of the 7 identified RGS4 inhibitors, we tested the compounds at an RGS4 construct with each of its 7 cysteine residues mutated to alanine. Figure 5 shows the loss of potency for inhibition of RGS4 by each of the 7 compounds at the cysless RGS4 mutant, indicating the likelihood that these compounds may act to alter the activity of RGS through the covalent modification of cysteine residues.
DISCUSSION
The potential utility of small molecules that disrupt the function of specific RGS proteins is manifold. Mechanistically, such inhibitors could be useful to increase the potency and selectivity of current GPCR agonist therapeutics, and may provide interesting pharmacological effects on their own. 12, 22, 23, 31 The current state of discovery efforts for RGS inhibitors has yet to identify a specific, potent, cell-permeant, and functional small molecule RGS inhibitor, but progress has been made in identifying ligands that can bind and disrupt RGS function in several systems. Initially, our lab identified a cyclic octapeptide based on the Switch 1 region of the RGS/Gαi1 crystal structure that inhibits the GAP activity of RGS4. 24, 25, 32 Another group identified compounds in a yeast-based screen, but no structural information or further report has been available. 26 Another small molecule, CCG-4986, was identified in our laboratory, appears to inhibit RGS4 function through irreversible cysteine modification, and does not inhibit RGS4 in intact cell systems, likely because of the reducing glutathione present in cells. 3 This study aimed to increase our ability to rapidly screen small molecule libraries for compounds that inhibit RGS function by disrupting its interaction with the G-protein Gαo. FCPIA provides a platform that allows us to multiplex our targets, as with the 5 RGS proteins screened in the assays described here. First, we demonstrated that the accurate measurement of these protein-protein interaction pairs could be accomplished in multiplex ( Figs. 2 and 3 , summarized in Table 1 ). These saturation experiments show that the presence of other RGS proteins in the mixture does not interfere with our ability to measure specific interaction. The saturation experiments also allowed us to assess the relative K d values for each RGS/Gαo interaction. We chose a screening concentration of Gαo (50 nM) that was in the linear portion of the RGS/Gαo to determine total binding, and in the absence of AlF 4 to determine the nonspecific component. In these experiments, each RGS was coupled to an individual bead region, washed, and then the beads mixed together before being added to the test wells. Nonspecific binding was subtracted from the total to yield the percentage of specific Gαo bound to the RGS (% Gαo bound in the presence of GDP-AlF 4 -, compared with GDP alone). In addition, nonspecific binding was tested to each bead region to ensure no intrinsic differences existed. Typical nonspecific binding was less than 10% total signal, except for RGS6, which had higher nonspecific binding (approximately 15%) at saturating Gαo concentration. Each line on the graph is the average of at least 3 independent experiments (n = 3), performed in duplicate, with error bars indicating the standard error of the mean (SEM). RGS, regulators of G-protein signaling. interaction saturation curves. By choosing this concentration, we increased the likelihood of detecting a disruption of the RGS/Gαo interaction.
These screens took place at a time when the limit of our available technology only allowed us to screen approximately two 96-well plates per hour, and we sought to increase the content value of our screens by multiplexing targets and compressing a small library to 4 compounds per well, resulting in 20 data points per experimental well. This increase allowed for the relatively slow (by HTS standards) FCPIA to be amenable to screening.
The results of our 8000-compound screens gave us initial hit rates of 1.5% to 3.9%. We further filtered those hits to identify wells that only met our 60% inhibition cutoff on a single RGS target, to focus on compounds that would be most promising in terms of specificity. This filtering resulted in a hit rate between 0.3% and 1.4%, considerably lower and more amenable to follow-up experiments. Each of the hit wells was deconvoluted, as all 4 compounds in a hit well were cherry-picked for dose-response experiments. For the follow-up, dose-response confirmation rates were between 4% and 15%, somewhat lower than the expected 25%, representing 1 of 4 compounds in the mixture having activity, but not outside of a reasonable confirmation range. With 30 compounds exhibiting doseresponse activity of 8000 screened, our overall confirmed hit rate is 0.375%.
The revelation of CCG-50014 acting as an inhibitor of the RGS16/Gαo interaction indicates the potential of false-negative wells in this screening paradigm, and our overall confirmation rate of 4% to 15% reflects the presence of false-positive wells. In these cases, false-positives could stem from several sources, such as cross-compound reactivity, compound/protein aggregation, or precipitation. It is unlikely that a spectral artifact of the combined compounds caused a well to be interpreted as a hit, because of the detection of fluorescence being gated on a beadevent. In addition, significant corruption of a bead's intrinsic spectral properties by a colored compound would result in a bead set being shifted outside of its tightly gated window on the Luminex, registering as a loss of events and not as a loss of bead-associated fluorescence. Every higher throughput method is subject to the generation of false-positives and falsenegatives. The FCPIA method eliminates or reduces 1 of the major sources of false-positives by virtually eliminating the effect of colored compounds in a well affecting the readout. In addition, our assay design of using 2 RGS family members and following up, using dose-response experiments, on each family member helps to identify the presence of family-specific inhibitors and reveal those compounds in wells that may otherwise be false-negatives.
Perhaps most interesting is that of 24 wells with activity in the primary screen for which confirmed active compounds were found, 18 wells yielded a single compound and 6 wells yielded 2 actives for a total of 30 confirmed actives. This shows that we can identify compounds with activity from the 4-component mixtures using our polyplexed system.
Given the similarity between the 3 members of the RGS4 family in our screen (4, 8, and 16), we followed up on each compound that had dose-response characteristics with each of In the table above, the number (percentage) of active wells was defined as those wells showing a 60% or greater inhibition of the G-protein signaling (RGS)/Gαo interaction for the indicated RGS. The number of unique wells indicates the number of wells for which only the single specified RGS was inhibited. Those unique wells were further analyzed in dose-response experiments, and the number compounds with activity following deconvolution of the 4 compounds from each active well is shown. The number of unique wells that produced an active compound is indicated in the last column. Thus, for RGS4 and RGS16 some wells produced more than 1 active compound, but for RGS6, 7, and 8 there was only 1 active compound (of the 4) in each well. Initial RGS "active"; a Lower potency in dose-response experiments; RGS, G-protein signaling. The table above shows individual compounds that had activity on more than 1 RGS as discovered in follow-up dose-response experiments. Superscripts after the compound number indicate the RGS at which the compound was originally identified as having activity, and the percentages indicate the amount of inhibition at 10 µM concentration of compound. For 2 compounds a , the level of inhibition was quite low at 10 µM, but these compounds did show dose-response activity, albeit with considerably higher IC 50 values. the 3 family members. Several of the compounds that were identified as hits on 1 RGS have activity, albeit lower than our 60% cutoff, at 10 µM, our approximate screening concentration. Interestingly, of the 25 compounds that had activity at 1 RGS among the R4 family members, 8 showed dose response on at least 1 of the other members of the R4 family, as shown in Table 3 .
In our previous experience, RGS4 is very sensitive to electrophonic compounds that may be able to covalently modify the cysteine residues on RGS4, resulting in a loss of activity. With this in mind, we created an RGS4 construct in which each of its 7 cysteine residues have been mutated to alanine. This "cysless" RGS4 binds Gαo with nearly identical affinity as the wild-type protein, and is not susceptible to the aforementioned inactivating modifications. When we retested 7 compounds that showed confirmatory dose-response activity on RGS4 ( Fig. 5A) , at the cysless RGS4 constructs, each of them exhibited a marked loss of potency (Fig. 5B) . This indicates that our most potent lead compounds, CCG-50014 and CCG-55919, likely act through a mechanism that involves the modification of cysteine residues on RGS4. Interestingly, 3 compounds still showed some inhibition at the cysless RGS4 construct, but only at high concentrations (>30 to 100 µM), where nonspecific effects such as aggregation or other artifacts may become problematic.
In conclusion, we have demonstrated the feasibility of using polyplexed FCPIA as a method to detect inhibitors of proteinprotein interactions. This study demonstrates the possibility of making multiple protein affinity measurements accurately within a single well, as well as the ability to deconvolute and identify single active compounds from complex mixtures. Using polyplexed FCPIA also provides an opportunity to have a series of concurrent counterscreens run in real-time with the highthroughput screen. With proper data curation via a database (M-Screen), we are able to identify potential "family-wide" inhibitors, as well as wells containing compounds that inhibit all measured activity. The increased content available using polyplexing with a negligible time penalty greatly increases the utility of using flow cytometry as a method of high-throughput screening for inhibitors of protein-protein interaction pairs. with all 7 cysteines mutated to alanine. A marked loss of potency for each of the compounds indicates a mechanism potentially involving the modification of cysteines in RGS4, which can inhibit RGS4 function. RGS, regulators of G-protein signaling.
